James W. Lee, MD; Edward P. Fox, MD; Pamela Rodgers-Johnson, MD; Clarence J. Gibbs Jr, PhD; Elaine DeFreitas, PhD; Angela Manns, MD, MPH; William Blattner, MD; James Cotelingam, MD; Pedro Piccardo, MD; Carlos Mora, MD; Jiri Safar, MD; Pawel Liberski, MD; Edward Sausville, MD, PhD; Jane Trepel, MD; Barnett S. Kramer, MD
Human T-cell lymphotropic virus, type 1 (HTLV-1), is the causative agent of both the acute and smoldering forms of adult T-cell leukemia-lymphoma, as shown by isolation of the virus from the leukemia cells and a rate of more than 90% antibody seropositivity for HTLV-1 in these patients (1-3). Mycosis fungoides is another HTLV-1-associated T-cell lymphoma, although seropositivity occurs in only 11% to 15% of patients (4). The virus is also associated with tropical spastic paraparesis and HTLV-1-associated myelopathy, identical chronic myeloneuropathies characterized by insidious spastic paraparesis and evidence of systemic and central nervous system HTLV-1 infection (5, 6).
Lee JW, Fox EP, Rodgers-Johnson P, Gibbs CJ, DeFreitas E, Manns A, et al. T-Cell Lymphoma, Tropical Spastic Paraparesis, and Malignant Fibrous Histiocytoma in a Patient with Human T-Cell Lymphotropic Virus, Type 1. Ann Intern Med. ;110:239–241. doi: 10.7326/0003-4819-110-3-239
Download citation file:
Published: Ann Intern Med. 1989;110(3):239-241.
Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use